Masao Torii, President and Representative Director of Boehringer Ingelheim Japan, Inc. discusses current trends in the global pharmaceutical market. He describes how Boehringer Ingelheim, one of the world’s largest pharmaceutical companies, uses its uniqueness and strengths to succeed globally. He also describes his company’s role in the Japanese pharmaceutical market, including how the corporate values of Boehringer Ingelheim Japan help cultivate global leaders within the company. This seminar provides guidance and insight for people interested in strategies to compete globally as well as how to develop your own skills to become a global leader.

Speaker: Mr. Masao Torii, President, Boehringer Ingelheim Japan, Inc.
Time and Date: 19:00 – 21:00, Tuesday, September 18, 2012
Venue: GLOBIS University, Tokyo, Japan
Language: English
Duration: 35:18

About Boehringer Ingelheim

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Boehringer Ingelheim has been developing its business in Japan for some 50 years. As a holding company, Boehringer Ingelheim Japan, Inc. manages four business segments under the following companies: Nippon Boehringer Ingelheim Co., Ltd. (prescription medicine), SSP CO., LTD. (Consumer Health Care), Boehringer Ingelheim Vetmedica Japan (veterinary medicines), and Boehringer Ingelheim Seiyaku (manufacture of pharmaceutical products).

Competing in the Global Pharmaceutical Market, Part 2

Duration: 45:37

Competing in the Global Pharmaceutical Market, Part 3

Duration: 18:22

Connect with Insights

Trouble keeping up with all the insights? Subscribe to our newsletter for monthly career inspiration right in your inbox!
Your newsletter subscription with us is subject to the GLOBIS Privacy Policy.